{Reference Type}: Systematic Review
{Title}: Effectiveness and duration of protection of primary and booster immunisation against meningococcal serogroup C disease with meningococcal conjugate C and ACWY vaccines: Systematic review.
{Author}: Griskaitis M;Thielemann I;Schönfeld V;Falman A;Scholz S;Reinacher U;Haas L;Wichmann O;Harder T;
{Journal}: J Infect
{Volume}: 89
{Issue}: 3
{Year}: 2024 Sep 10
{Factor}: 38.637
{DOI}: 10.1016/j.jinf.2024.106228
{Abstract}: <B>OBJECTIVE: </B>To estimate vaccine effectiveness (VE) and duration of protection of single primary and booster immunisation with meningococcal C (MenC) and ACWY (MenACWY) conjugate vaccines in preventing MenC invasive meningococcal disease (IMD).<BR><B>METHODS: </B>We performed a systematic review on studies of VE and immunogenicity (rSBA/hSBA titers) of participants aged 12-23 months for primary and 6-18 years for booster immunisation (last search: 18 August 2023). Risk of bias and certainty of evidence were evaluated (PROSPERO: CRD42020178773).<BR><B>RESULTS: </B>We identified 10 studies. Two studies reported VE of primary immunisation with MenC vaccines ranging between 90% (74.9 - 96.1) and 84.1% (41.5 - 95.7) for periods of 2 and 7 years, respectively. Eight studies reported immunogenicity of primary immunisation with MenC and/or MenACWY vaccines, of which two reported -in addition- on booster immunisation. The percentage of participants with protective rSBA titers was high after primary immunisation but waned over the following 6 years. A single booster at the age of 7 years or older seems to prolong protection for several years.<BR><B>CONCLUSIONS: </B>A single dose of MenC or MenACWY vaccine at 12-23 months of age provides robust protection against MenC IMD. Data on booster immunisation are sparse, but indicate prolonged protection for three years at least.